Small lymphocytic lymphoma (SLL) is a slow-growing cancer of the immune system. It is typically manageable with treatment, but outlook can depend on a few factors. SLL is one type of non-Hodgkin ...

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are very similar because they have the same type of ...

Background: Small lymphocytic lymphoma is a relatively rare B-cell non-Hodgkin lymphoma that is considered to be the tissue equivalent of the much more common entity chronic lymphocytic leukemia.

CLL or SLL in people who have received a prior Bruton’s tyrosine kinase (BTK) inhibitor and B-cell lymphoma 2 (BCL-2) treatment plan. Jaypirca starts working soon after you start taking the ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

The drug has been approved for relapsed/refractory (r/r) CLL/SLL, r/r marginal zone lymphoma and r/r mantle cell lymphoma on China's National Reimbursement Drug List. InnoCare Pharma focuses on ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...

Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain, which enhances ...